Tao Yu, a graduate student in the Department of Biomedical Engineering, talks about his internship with Biohealth Innovation, through the Johns Hopkins University School of Medicine’s Biomedical Careers Initiative (BCI).
View the interview here.
Boards aren’t working. It’s been more than a decade since the first wave of post-Enron regulatory reforms and, despite a host of guidelines from independent watchdogs such as the International Corporate Governance Network, most boards aren’t delivering on their core mission: providing strong oversight and strategic support for management’s efforts to create long-term value.
The Swiss firm, which this week filed a melanoma combination drug for US approval, spent $10bn on research into new products, ahead of rivals such as Novartis, which spent $9.8bn and the $8.2bn spent by Johnson & Johnson (J&J).
Shareholders in British drugmaker GlaxoSmithKline (GSK.L) have approved a planned deal with Switzerland’s Novartis (NOVN.VX), which will see the two pharmaceutical groups trade more than $20 billion (12.7 billion pounds) of assets.
A coalition of geneticists and computer programmers calling itself the Global Alliance for Genomics and Health is developing protocols for exchanging DNA information across the Internet. The researchers hope their work could be as important to medical science as HTTP, the protocol created by Tim Berners-Lee in 1989, was to the Web.
Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS) (formerly Marika, Inc.), a Nevada corporation, announced today its successful completion of a share exchange transaction with Pieris AG, a German stock corporation pursuant to which Pieris AG became a wholly-owned subsidiary of the Company. The combined entity is named Pieris Pharmaceuticals, Inc. and will focus solely on the business of Pieris AG, a clinical-stage biopharmaceutical company dedicated to the discovery and development of its proprietary Anticalin® class of biotherapeutics. The share exchange transaction was effected on December 17, 2014, and beginning on December 18, 2014, Pieris will trade under the symbol “PIRS” on the OTC Markets.
United Therapeutics (Nasdaq: UTHR) announced two senior executive promotions as well as changes to Martine Rothblatt, Ph.D’s compensation program.
University of Massachusetts President Robert Caret will take over as University System of Maryland’s fourth chancellor in July.
Let’s be clear: Martine Rothblatt is just plain more of a lawyer than anybody else in this town.
The 60-year-old grandmother and CEO of United Therapeutics, the Silver Spring-based biotech she founded to help save her younger daughter’s life, banked $38 million last year. It made her the nation’s highest-paid female executive. It also made her the nation’s highest-paid transgendered person, as she had sex reassignment surgery in 1994.
The FDA offered up an early retrospective of the 2014 year of approvals Friday with a rundown the regulator feels pretty good about. “Our Center for Drug Evaluation and Research (CDER) has so far approved 35 novel drugs in 2014 compared to 27 in 2013,” FDA commissioner Margaret Hamburg wrote on the agency’s FDA Voice blog.